Search Result

Results for "

MI

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (2) Androgen Receptor (1) Angiotensin-converting Enzyme (ACE) (2) Apoptosis (8) Bacterial (2) E1/E2/E3 Enzyme (4) E3 Ligase Ligand-Linker Conjugates (1) Endogenous Metabolite (4) Epigenetic Reader Domain (9) Fluorescent Dye (1) GnRH Receptor (1) HCV (1) HDAC (1) HIF/HIF Prolyl-Hydroxylase (1) Histone Demethylase (4) Huntingtin (1) Integrin (4) Isotope-Labeled Compounds (1) MALT1 (1) MDM-2/p53 (4) Mitochondrial Metabolism (4) NO Synthase (4) Parasite (1) PI4K (1) PKC (2) PROTACs (1) Reactive Oxygen Species (1) SARS-CoV (1) Sigma Receptor (2) Toll-like Receptor (TLR) (1)
By Research Areas:	Cancer (24) Cardiovascular Disease (15) Infection (4) Inflammation/Immunology (3) Metabolic Disease (1) Neurological Disease (5)

By Targets:

Akt (2)

Androgen Receptor (1)

Angiotensin-converting Enzyme (ACE) (2)

Apoptosis (8)

Bacterial (2)

E1/E2/E3 Enzyme (4)

E3 Ligase Ligand-Linker Conjugates (1)

Endogenous Metabolite (4)

Epigenetic Reader Domain (9)

Fluorescent Dye (1)

GnRH Receptor (1)

HCV (1)

HDAC (1)

HIF/HIF Prolyl-Hydroxylase (1)

Histone Demethylase (4)

Huntingtin (1)

Integrin (4)

Isotope-Labeled Compounds (1)

MALT1 (1)

MDM-2/p53 (4)

Mitochondrial Metabolism (4)

NO Synthase (4)

Parasite (1)

PI4K (1)

PKC (2)

PROTACs (1)

Reactive Oxygen Species (1)

SARS-CoV (1)

Sigma Receptor (2)

Toll-like Receptor (TLR) (1)

By Research Areas:

Cancer (24)

Cardiovascular Disease (15)

Infection (4)

Inflammation/Immunology (3)

Metabolic Disease (1)

Neurological Disease (5)

Inhibitors & Agonists

Fluorescent Dye

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-136688

MI-389	PROTACs	Cancer
MI-389 is a PROTAC translation termination factor GSPT1 degrader. MI-389 disrupts a target that is a shared dependency in different AML and ALL cell lines, and that MI-389 action is dependent on the CRL4 ^CRBN E3 ligase .

HY-19319

MI-136	Epigenetic Reader Domain Androgen Receptor Apoptosis	Cancer
MI-136 is an inhibitor of the menin-MLL protein-protein interaction (PPI), with an IC₅₀ of 31 nM and a K_d of 23.6 nM. MI-136 shows to block AR signaling and has the potential for the study in castration-resistant tumors .

HY-P2357

MI-1544	GnRH Receptor	Metabolic Disease
MI-1544 is a powerful GnRH antagonist. MI-1544 induces inhibitory effects on the pituitary LH release and on gonads. MI-1544 can be used for the research of antifertility effect .

HY-150737

MI-1851	SARS-CoV	Infection
MI-1851 is a potent furin inhibitor. MI-1851 prevents the proteolytic processing of the S protein of SARS-CoV-2 by endogenous flavoprotease in HEK293 cells. MI-185 has antiviral activity .

HY-110264

MI-192	HDAC Apoptosis	Neurological Disease Cancer
MI-192 is a selective HDAC2 and HDAC3 inhibitor with IC₅₀s of 30 nM and 16 nM, respectively. MI-192 is more selective for HDAC2/3 than other HDAC isomers.MI-192 induces myeloid leukaemic cells apoptosis. Anticaner and neuroprotective activities .

HY-117365

MI-1481	Others	Cancer
MI-1481 is a highly potent inhibitor of the Menin-MLL1 interaction with IC₅₀ of 3.6 nM. MI-1481 markedly reduces cell growth of murine bone marrow cells transformed and inhibits leukemia progression .

HY-17493

MI-773 4 Publications Verification	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
MI-773 is a potent MDM2-p53 protein‐protein interaction (PPI) inhibitor with high binding affinity against MDM2 (K_d=8.2 nM). MI-773 has antitumor activity .

HY-19810

MI-538

3 Publications Verification

Epigenetic Reader Domain Cancer

MI-538 is an inhibitor of the interaction between menin and MLL fusion proteins with an IC₅₀ of 21 nM.
HY-111937

MI-1

Epigenetic Reader Domain Cancer

MI-1 inhibits Menin-MLL interaction with an IC₅₀ of 1.9 μM .
HY-19809

MI-463

1 Publications Verification

Epigenetic Reader Domain Cancer

MI-463 is a highly potent and orally bioavailable small molecule inhibitor of the menin-mLL interaction.
HY-16925

MI-503

5+ Cited Publications

Epigenetic Reader Domain Cancer

MI-503 is a highly potent and orally bioavailable small molecule inhibitor of the menin-mLL interaction.

MI-538 3 Publications Verification	Epigenetic Reader Domain	Cancer
MI-538 is an inhibitor of the interaction between menin and MLL fusion proteins with an IC₅₀ of 21 nM.

MI-1	Epigenetic Reader Domain	Cancer
MI-1 inhibits Menin-MLL interaction with an IC₅₀ of 1.9 μM .

MI-463 1 Publications Verification	Epigenetic Reader Domain	Cancer
MI-463 is a highly potent and orally bioavailable small molecule inhibitor of the menin-mLL interaction.

MI-503 5+ Cited Publications	Epigenetic Reader Domain	Cancer
MI-503 is a highly potent and orally bioavailable small molecule inhibitor of the menin-mLL interaction.

HY-108350

MI-2-2	Epigenetic Reader Domain	Cancer
MI-2-2 is a potent menin-MLL inhibitor. MI-2-2 binds to menin with low nanomolar affinity (K_d=22nM) and very effectively disrupts the bivalent protein-protein interaction between menin and MLL. MI-2-2 has specific and very pronounced activity in MLL leukemia cells, including inhibition of cell proliferation, down-regulation of Hoxa9 expression, and differentiation .

HY-125858

MI-1061 1 Publications Verification	MDM-2/p53 E1/E2/E3 Enzyme Apoptosis	Cancer
MI-1061 is a potent, orally bioavailable, and chemically stable MDM2 (MDM2-p53 interaction) inhibitor (IC₅₀=4.4 nM; K_i=0.16 nM). MI-1061 potently activates p53 and induces apoptosis in the SJSA-1 xenograft tumor tissue in mice. Anti-tumor activity .

HY-136360

MI-3454 2 Publications Verification	Epigenetic Reader Domain	Cancer
MI-3454 is an orally active, highly potent and selective menin-MLL1 interaction inhibitor with an IC₅₀ of 0.51 nM. MI-3454 inhibits proliferation, induces differentiation and complete remission or regression of leukemia in mouse models of MLL1-rearranged or NPM1-mutated leukemia through downregulation of key genes involved in leukemogenesis .

HY-18986

SAR405838 MI-77301	MDM-2/p53 E1/E2/E3 Enzyme Apoptosis	Cancer
SAR405838 (MI-77301), an analog of MI-773, is a highly potent and selective MDM2-p53 interaction inhibitor. SAR405838 binds to MDM2 with a K_i of 0.88 nM. SAR405838 induces apoptosis and has potent antitumor activity .

HY-125858A

MI-1061 TFA 1 Publications Verification	MDM-2/p53 E1/E2/E3 Enzyme Apoptosis	Cancer
MI-1061 TFA is a potent, orally bioavailable, and chemically stable MDM2 (MDM2-p53 interaction) inhibitor (IC₅₀=4.4 nM; K_i=0.16 nM). MI-1061 TFA potently activates p53 and induces apoptosis in the SJSA-1 xenograft tumor tissue in mice. Anti-tumor activity .

HY-110248

MI 14	PI4K HCV	Infection
MI 14 is a selective PI4KIIIβ inhibitor with IC₅₀s of 54 nM, >100 μM, >100 μM for PI4KIIIβ, PI4KIIIα, PI4KIIα, respectively. MI 14 has antiviral activity against HCV 1b, CVB3, HRVM, HVC 2a .

HY-15223

MI-3 1 Publications Verification Menin-MLL inhibitor 3	Epigenetic Reader Domain Apoptosis	Cancer
MI-3 (Menin-MLL inhibitor 3) is a potent and high affinity menin-MLL inhibitor with an IC₅₀ of 648 nM and a K_d of 201 nM .

HY-18986S

SAR405838-d10 MI-77301-d₁₀	Isotope-Labeled Compounds	Cancer
SAR405838-d₁₀ (MI-77301-d₁₀) is the deuterium labeled SAR405838 (HY-18986). SAR405838 (MI-77301), an analog of MI-773, is a highly potent and selective MDM2-p53 interaction inhibitor. SAR405838 binds to MDM2 with a K_i of 0.88 nM. SAR405838 induces apoptosis and has potent antitumor activity .

HY-D1781

NTPAN-MI	Fluorescent Dye	Others
NTPAN-MI is a fluorescent probe. NTPAN-MI is selectively activated upon labeling unfolded proteins with exposed thiols, thereby reporting on the extent of proteostasis .

HY-125858B

(S,R,S)-MI-1061	Others	Others
(S,R,S)-MI-1061 is the isomer of MI-1061(HY-125858). (S,R,S)-MI-1061 can used to synthesize Antibody-Drug Conjugates (ADCs). MI-1061 is a potent, orally bioavailable, and chemically stable MDM2 (MDM2-p53 interaction) inhibitor (IC₅₀=4.4 nM; K_i=0.16 nM). MI-1061 potently activates p53 and induces apoptosis in the SJSA-1 xenograft tumor tissue in mice. Anti-tumor activity .

HY-12276

MALT1 inhibitor MI-2 4 Publications Verification	MALT1	Cancer
MALT1 inhibitor MI-2 is a MALT1 inhibitor (IC₅₀=5.84 μM). MALT1 inhibitor MI-2 binds directly to MALT1, irreversibly suppresses protease function and is accompanied by NF-κB reporter activity suppression, c-REL nuclear localization inhibition, and NF-κB target gene downregulation. MALT1 inhibitor MI-2 shows nontoxic to animals .

HY-15222

Menin-MLL inhibitor MI-2 2 Publications Verification	Epigenetic Reader Domain Apoptosis	Cancer
Menin-MLL inhibitor MI-2 is a Menin-MLL interaction inhibitor with IC₅₀ of 446±28 nM.

HY-143218

TPE-MI 1 Publications Verification Tetraphenylethene maleiMIde	Huntingtin Parasite	Neurological Disease
TPE-MI (Tetraphenylethene maleimide) is a thiol probe for measuring unfolded protein load and proteostasis in cells. TPE-MI can report imbalances in proteostasis in induced pluripotent stem cell models of Huntington disease, as well as cells transfected with mutant Huntington exon 1 before the formation of visible aggregates. TPE-MI also detects protein damage following dihydroartemisinin research of the malaria parasitesPlasmodium falciparum .

HY-130272

Anti-MI/R injury agent 1	Others	Cardiovascular Disease
Anti-MI/R injury agent 1 (compound 18), a Panaxatriol derivative, is an orally active, potent anti-myocardial ischemia/reperfusion (anti-MI/R) injury agent. Anti-MI/R injury agent 1 enhances oxygen-glucose deprivation and reperfusion (OGD/R)-induced cardiomyocyte injury cell viability. Anti-MI/R injury agent 1 can markedly reduce myocardial infarction size, decrease circulating cardiac troponin I (cTnI) leakage, and alleviate cardiac tissue damage in the rats .

HY-130854

Thalidomide-NH-C6-NH-Boc	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-NH-C6-NH-Boc is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used for MI-389 (compound 22) synthesis. MI-389 is a potent phthalimide PROTAC degrader based on the multi-targeted receptor tyrosine kinase inhibitor sunitinib (HY-10255A) .

HY-161344

Z36-MP5	Others	Cancer
Z36-MP5 is an Mi-2β-targeted inhibitor, with IC₅₀ of 0.082 μM. Z36-MP5 can reduce Mi-2β ATPase activity and reactivates ISG transcription. Z36-MP5 can stimulate T-cell-mediated cytotoxicity .

HY-B0592

Trandolapril RU44570	Angiotensin-converting Enzyme (ACE)	Cardiovascular Disease
Trandolapril (RU44570) is a nonsulfhydryl proagent that is hydrolysed to the active diacid Trandolaprilat. Trandolapril is an orally administered angiotensin converting enzyme (ACE) inhibitor that has been used in the treatment of hypertension and congestive heart failure (CHF), and after myocardial infarction (MI) .

HY-B0592A

Trandolapril hydrochloride RU44570 hydrochloride	Angiotensin-converting Enzyme (ACE)	Cardiovascular Disease
Trandolapril (RU44570) hydrochloride is a nonsulfhydryl proagent that is hydrolysed to the active diacid Trandolapril hydrochlorideat. Trandolapril hydrochloride is an orally active angiotensin converting enzyme (ACE) inhibitor that has been used in the treatment of hypertension and congestive heart failure (CHF), and after myocardial infarction (MI) .

HY-B1409S

Isosorbide dinitrate-13C6 ISDN-¹³C₆	NO Synthase	Cardiovascular Disease
Isosorbide dinitrate- ¹³C₆ is the ¹³C labeled Isosorbide dinitrate[1]. Isosorbide dinitrate (ISDN) is an NO donor that prevents LV remodeling and degradation of cardiac function following myocardial infarction (MI)[2].

HY-B1409

Isosorbide dinitrate ISDN	NO Synthase	Cardiovascular Disease
Isosorbide dinitrate (ISDN) is an NO donor that prevents LV remodeling and degradation of cardiac function following myocardial infarction (MI) .

HY-N10561

Wychimicin A	Bacterial	Infection
Wychimicin A is a spirotetronate polyketide, can be isolated from the rare actinomycete Actinocrispum wychmicini strain MI503-AF4. Wychimicin A shows strong antibacterial activity against methicillin-resistant Staphylococcus. aureus (IC₅₀=0.125-0.5 μg/mL) and Enterococcus. faecalis/faecium (IC₅₀=0.125-0.25 μg/mL) .

HY-N10560

Wychimicin C	Bacterial	Infection
Wychimicin C is a spirotetronate polyketide, can be isolated from the rare actinomycete Actinocrispum wychmicini strain MI503-AF4. Wychimicin C shows strong antibacterial activity against methicillin-resistant Staphylococcus. aureus (IC₅₀=0.125-0.5 μg/mL) and Enterococcus. faecalis/faecium (IC₅₀=0.125-0.25 μg/mL) .

HY-119350B

Zalunfiban dihydrochloride RUC-4 dihydrochloride	Integrin	Cardiovascular Disease
Zalunfiban (RUC-4) dihydrochloride is a potent, selective platelet αIIbβ3 antagonist (IC₅₀=45 nM). Zalunfiban dihydrochloride can be used for the research of myocardial infarction (MI) .

HY-119350

Zalunfiban RUC-4	Integrin	Cardiovascular Disease
Zalunfiban (RUC-4) is a potent, selective platelet αIIbβ3 antagonist (IC₅₀=45 nM). Zalunfiban can be used for the research of myocardial infarction (MI) .

HY-119350C

Zalunfiban acetate RUC-4 acetate	Integrin	Cardiovascular Disease
Zalunfiban (RUC-4) acetate is a potent, selective platelet αIIbβ3antagonist (IC₅₀=45 nM). Zalunfiban acetate can be used for the research of myocardial infarction (MI) .

HY-106262

Delcasertib KAI-9803; BMS-875944	PKC	Cardiovascular Disease Inflammation/Immunology
Delcasertib (KAI-9803) is a potent and selective δ-protein kinase C (δPKC) inhibitor. Delcasertib (KAI-9803) could ameliorate injury associated with ischemia and reperfusion in animal models of acute myocardial infarction (MI) .

HY-106262B

Delcasertib hydrochloride 1 Publications Verification KAI-9803 hydrochloride; BMS-875944 hydrochloride	PKC	Cardiovascular Disease Inflammation/Immunology
Delcasertib (KAI-9803) hydrochloride is a potent and selective δ-protein kinase C (δPKC) inhibitor. Delcasertib (KAI-9803) hydrochloride could ameliorate injury associated with ischemia and reperfusion in animal models of acute myocardial infarction (MI) .

HY-P99891

Rovelizumab	Integrin	Cardiovascular Disease
Rovelizumab is a humanized monoclonal leukointegrin antibody. Rovelizumab is a monoclonal antibody directed against the CD11/CD18 cell adhesion proteins. Rovelizumab can be used for research of multiple sclerosis (MS), hemorrhagic shock, myocardial infarction (MI) and stroke .

HY-123422

GSK360A	HIF/HIF Prolyl-Hydroxylase	Cardiovascular Disease
GSK360A is a potent and orally active HIF-PHD inhibitor with IC₅₀ values of 10, 100, and 126 nM for PHD1, PHD2, and PHD3, respectively. GSK360A activates the HIF-1 alpha pathway and protect the failing heart after myocardial infarction (MI) .

HY-149586

ROS-IN-2	Reactive Oxygen Species	Others
ROS-IN-2 (compound 85) is a seco-lupane triterpenoid derivative. ROS-IN-2 blocks ROS production and protects mitochondria from damage by inhibiting excessive production of oxidative stressors. ROS-IN-2 can be used for myocardial ischemia/reperfusion (MI/R) injury research .

HY-18100A

PRE-084 hydrochloride Maximum Cited Publications 7 Publications Verification	Sigma Receptor Akt NO Synthase	Cardiovascular Disease Neurological Disease
PRE-084 hydrochloride is a highly selective σ1 receptor (S1R) agonist, with an IC₅₀ of 44 nM. PRE-084 hydrochloride exhibits good neuroprotective effects, can improve motor function and motor neuron survival in mice. PRE-084 hydrochloride also can ameliorate myocardial ischemia-reperfusion injury in rats by activating the Akt-eNOS pathway .

HY-113039

L-2-Hydroxyglutaric acid (S)-2-Hydroxyglutaric acid	Histone Demethylase Mitochondrial Metabolism Endogenous Metabolite	Cancer
L-2-Hydroxyglutaric acid is an epigenetic modifier and putative oncometabolite in renal cancer. L-2-Hydroxyglutaric acid can inhibit histone demethylases and hence promote histone methylation . L-2-Hydroxyglutaric acid inhibits mitochondrial creatine kinase (Mi-CK) activity with K_m and K_i of 2.52 mM and 11.13 mM, respectively .

HY-W015114

L-2-Hydroxyglutaric acid disodium (S)-2-Hydroxyglutaric acid disodium	Histone Demethylase Mitochondrial Metabolism Endogenous Metabolite	Cancer
L-2-Hydroxyglutaric acid disodium is an epigenetic modifier and putative oncometabolite in renal cancer. L-2-Hydroxyglutaric acid disodium can inhibit histone demethylases and hence promote histone methylation . L-2-Hydroxyglutaric acid inhibits mitochondrial creatine kinase (Mi-CK) activity with K_m and K_i of 2.52 mM and 11.13 mM, respectively .

HY-18100

PRE-084	Sigma Receptor Akt NO Synthase	Cardiovascular Disease Neurological Disease
PRE-084 is a highly selective σ1 receptor (S1R) agonist, with an IC₅₀ of 44 nM. PRE-084 exhibits good neuroprotective effects, can improve motor function and motor neuron survival in mice. PRE-084 also can ameliorate myocardial ischemia-reperfusion injury in rats by activating the Akt-eNOS pathway .

HY-141537

ABR-238901 4 Publications Verification	Toll-like Receptor (TLR)	Inflammation/Immunology
ABR-238901 is an orally active and potent S100A8/A9 blocker and inhibits S100A8/A9 interaction with its receptors RAGE (receptor for advanced glycation endproducts) and TLR4 (toll-like receptor 4). ABR-238901 has the potential for myocardial infarction (MI) research .

HY-113039R

L-2-Hydroxyglutaric acid (Standard) (S)-2-Hydroxyglutaric acid (Standard)	Histone Demethylase Mitochondrial Metabolism Endogenous Metabolite	Cancer
L-2-Hydroxyglutaric acid (Standard) is the analytical standard of L-2-Hydroxyglutaric acid. This product is intended for research and analytical applications. L-2-Hydroxyglutaric acid is an epigenetic modifier and putative oncometabolite in renal cancer. L-2-Hydroxyglutaric acid can inhibit histone demethylases and hence promote histone methylation . L-2-Hydroxyglutaric acid inhibits mitochondrial creatine kinase (Mi-CK) activity with K_m and K_i of 2.52 mM and 11.13 mM, respectively .

HY-W015114R

L-2-Hydroxyglutaric acid disodium (Standard) (S)-2-Hydroxyglutaric acid disodium (Standard)	Histone Demethylase Mitochondrial Metabolism Endogenous Metabolite	Cancer
L-2-Hydroxyglutaric acid (disodium) (Standard) is the analytical standard of L-2-Hydroxyglutaric acid (disodium). This product is intended for research and analytical applications. L-2-Hydroxyglutaric acid disodium is an epigenetic modifier and putative oncometabolite in renal cancer. L-2-Hydroxyglutaric acid disodium can inhibit histone demethylases and hence promote histone methylation . L-2-Hydroxyglutaric acid inhibits mitochondrial creatine kinase (Mi-CK) activity with K_m and K_i of 2.52 mM and 11.13 mM, respectively .

HY-125959

Ucf-101	Apoptosis	Cardiovascular Disease Neurological Disease
Ucf-101 is a selective and competitive inhibitor of pro-apoptotic protease Omi/HtrA2, with an IC₅₀ of 9.5 μM for His-Omi. Ucf-101 exhibits very little activity against various other serine proteases (IC₅₀>200 μM). Ucf-101 has a natural red fluorescence at 543 nm that is used to monitor its ability to enter mammalian cells. Ucf-101 has a significant cardioprotective effect against MI/R injury and also has certain neuroprotective effect .

Cat. No.	Product Name	Category	Target	Chemical Structure